Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The host gut mucosa and microbiota represent a complex symbiotic ecosystem consisting of the intestinal epithelial lining, the overlying mucus layer, and trillions of microorganisms including bacteria, fungi, and viruses (Thursby & Juge, 2017, PMID: 28539185). This system plays a critical role in human health by facilitating nutrient absorption, synthesizing essential vitamins like K and B12, and training the host immune system to distinguish between commensal organisms and pathogens (NIH, 2023). The gut microbiota also produces metabolic byproducts, such as short-chain fatty acids (SCFAs), which maintain the integrity of the intestinal barrier and influence systemic physiology through the gut-brain and gut-liver axes (Fan & Pedersen, 2021, PMID: 33199854). Dysregulation of this environment, known as dysbiosis, is linked to numerous conditions including inflammatory bowel disease (IBD), metabolic syndrome, and Clostridioides difficile infection (CDI) (CDC, 2022). Therapeutic interventions, such as probiotics, prebiotics, and fecal microbiota transplantation (FMT), aim to restore a healthy microbial balance or enhance the protective functions of the mucosal barrier (FDA, 2022). While targeting this system offers significant therapeutic potential, challenges include the high variability of microbial composition between individuals and the risk of systemic infection in immunocompromised patients (Gupta et al., 2016, PMID: 27107786).
Modulation of microbial composition, restoration of intestinal barrier integrity, competitive inhibition of pathogens, and regulation of mucosal immune cell trafficking.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host gut mucosa and microbiota.